MedTrace Logo

Sildenafil for Chronic Obstructive Pulmonary Disease

NCT00104637 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2012-05-21

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine if sildenafil improves the exercise capacity and lung function of patients with chronic obstructive pulmonary disease.

Conditions

  • Pulmonary Disease, Chronic Obstructive
  • Emphysema

Interventions

DRUG

sildenafil citrate

sildenafil citrate 25 mg by mouth thrice daily (po tid)

DRUG

Placebo

25 mg po tid

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • Kawut, Steven, MD

    lead INDIV

Principal Investigators

  • Steven M Kawut, M.D., M.S. · Columbia University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-02-28
Primary Completion
2008-11-30
Completion
2008-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00104637 on ClinicalTrials.gov